Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

British Journal of Haematology
Francesco d'AmoreHans Hagberg

Abstract

The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated. Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks. Median age was 69 years (range 26-85). Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV). Objective tumour responses were obtained in 24% of the patients with two complete responses unconfirmed (CRu) and three partial responses (PR). One of the CRus lasted more than 252 d. Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1). In general, the trial drug was well tolerated with no major toxicity. Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatm...Continue Reading

References

Feb 1, 1996·Journal of Clinical Pathology·E MatutesD Catovsky
Sep 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J R AndersonD D Weisenburger
Oct 28, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A López-GuillermoE Montserrat
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E OlsenJ Nichols
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T RüdigerUNKNOWN Non-Hodgkin's Lymphoma Classification Project
Mar 23, 2002·Leukemia & Lymphoma·Rakhshandra TalpurMadeleine Duvic
Aug 16, 2002·Medical Oncology·Claire E DeardenDaniel Catovsky
Feb 13, 2003·American Journal of Clinical Pathology·Jonathan JucoShiyong Li
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Mar 31, 2006·Cytometry. Part B, Clinical Cytometry·Weina ChenSteven H Kroft
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip WentStefano A Pileri
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Jan 20, 2007·British Journal of Haematology·Nam H DangLuis Fayad
May 23, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen M AnsellPeter Borchmann
Jun 24, 2008·Journal of Immunotoxicology·John C MorrisJohn E Janik
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Oct 8, 2008·International Journal of Hematology·Katja C WeiselMarion Subklewe
Feb 21, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sukyung WooWilliam D Figg

❮ Previous
Next ❯

Citations

Aug 17, 2011·Current Oncology Reports·Eileen M Boyle, Franck Morschhauser
Jun 11, 2010·International Journal of Hematology·Jasmine M Zain, Owen O'Connor
Feb 22, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M DreylingE Zucca
Sep 26, 2012·The Cancer Journal·Michael Youngjun Choi, Mary Jo Lechowicz
Dec 14, 2011·Hematology·Kerry J Savage
Feb 11, 2014·International Journal of Hematology·Andrew M Intlekofer, Anas Younes
Sep 18, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Thomas SchirrmannStefan Barth
Apr 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P CorradiniS Tura
Dec 29, 2010·Advances in Hematology·Y Y Hwang, R H S Liang
Feb 11, 2014·Leukemia & Lymphoma·Marco CalvarusoAda Maria Florena
Mar 20, 2014·Expert Opinion on Emerging Drugs·Michael Dickinson, Henry Miles Prince
Mar 15, 2011·Expert Opinion on Biological Therapy·Sam MayesTim M Illidge
Oct 18, 2014·Expert Opinion on Investigational Drugs·Doraid Alrifai, Ruth Pettengell
Nov 19, 2015·Expert Opinion on Investigational Drugs·David GhezVincent Ribrag
Jan 29, 2014·Seminars in Hematology·Kailash MosalpuriaJulie M Vose
Jan 29, 2014·Seminars in Hematology·Mehdi HamadaniMohamed A Kharfan-Dabaja
Jun 5, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Franck MorschhauserBertrand Coiffier
Jan 10, 2012·International Journal of Pharmaceutics·John G ElvinChristopher F van der Walle
Apr 13, 2011·British Journal of Haematology·Anton B AlexandroffMartin J S Dyer
Apr 13, 2011·British Journal of Haematology·Claire E DeardenUNKNOWN British Committee for Standards in Haematology
Oct 5, 2015·Dermatologic Clinics·Larisa J Geskin
Sep 8, 2015·Future Oncology·Eve Gallop-Evans
Jul 16, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Anna CzajczynskaMartin Gramatzki
Apr 14, 2016·Journal of Hematology & Oncology·Yaping ZhangJianyong Li
Jun 12, 2012·MAbs·Niels W C J van de Donk, Eugen Dhimolea
Sep 10, 2014·Cancer Treatment Reviews·Bertrand CoiffierPier Luigi Zinzani
Dec 16, 2016·Expert Opinion on Biological Therapy·Jogender Tushir-Singh
Mar 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michinori OguraRyuzo Ueda
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BrodyRonald Levy
Jun 1, 2011·Therapeutic Advances in Hematology·Francine Foss
Jan 20, 2018·Oncotarget·Kevin G PinzYupo Ma
Mar 23, 2011·Expert Review of Anticancer Therapy·Rebecca A Howman, H Miles Prince
Sep 24, 2011·Expert Review of Hematology·Fernando RoncolatoPier Paolo Piccaluga
Mar 27, 2013·American Journal of Therapeutics·Nadia Khan, Bruce D Cheson
Mar 21, 2019·Frontiers in Oncology·Lauren D SchererMaksim Mamonkin
Oct 22, 2020·International Journal of Molecular Sciences·Fátima Bayón-CalderónSara González-García
Feb 28, 2014·Cancer Research·Yanping WangHyung L Kim
Jul 27, 2021·Chinese Medical Journal·Min Wei, Yi-Ming Shao
Oct 9, 2021·Stem Cell Research & Therapy·Pouya Safarzadeh KozaniFatemeh Rahbarizadeh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.